Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

• Subjects who achieve (yes/no): body weight reduction more than or equal to 10%[ Time Frame: Week 0, week 104 ]
  Number of subjects
• Subjects who achieve (yes/no): body weight reduction more than or equal to 15%[ Time Frame: Week 0, week 104 ]
  Number of subjects
• Change in waist circumference[ Time Frame: Week 0, week 104 ]
  Measured in cm
• Change in systolic blood pressure[ Time Frame: Week 0, week 104 ]
  Measured in mmHg
• Change in body weight[ Time Frame: Week 0, week 104 ]
  Measured in kg
• Change in body mass index (BMI)[ Time Frame: Week 0, week 104 ]
  Measured in kg/m^2
• Change in hemoglobin A1c (HbA1c)[ Time Frame: Week 0, week 104 ]
  Measured in %
• Change in HbA1c[ Time Frame: Week 0, week 104 ]
  Measured in mmol/mol
• Change in fasting plasma glucose[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in fasting serum insulin[ Time Frame: Week 0, week 104 ]
  Measured in micro IU/mL
• Change in diastolic blood pressure[ Time Frame: Week 0, week 104 ]
  Measured in mmHg
• Change in total cholesterol[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in high density lipoprotein (HDL) cholesterol[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in low density lipoprotein (LDL) cholesterol[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in very low density lipoprotein (VLDL) cholesterol[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in free fatty acids[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in triglycerides[ Time Frame: Week 0, week 104 ]
  Measured in mg/dL
• Change in high sensitivity C-Reactive Protein[ Time Frame: Week 0, week 104 ]
  Measured in mg/L
• Change in body weight[ Time Frame: Week 0, week 52 ]
  Measured in %
• Change in body weight[ Time Frame: Week 0, week 52 ]
  Measured in kg
• Change in BMI[ Time Frame: Week 0, week 52 ]
  Measured in kg/m^2
• Change in waist circumference[ Time Frame: Week 0, week 52 ]
  Measured in cm
• Subjects who achieve (yes/no): body weight reduction more than or equal to 5%[ Time Frame: Week 0, week 52 ]
  Number of subjects
• Subjects who achieve (yes/no): body weight reduction more than or equal to 10%[ Time Frame: Week 0, week 52 ]
  Number of subjects
• Subjects who achieve (yes/no): body weight reduction more than or equal to 15%[ Time Frame: Week 0, week 52 ]
  Number of subjects
• Number of treatment-emergent adverse events (TEAEs)[ Time Frame: Week 0, week 111 ]
  Number of events
• Number of serious adverse events (SAEs)[ Time Frame: Week 0, week 111 ]
  Number of events
• Change in pulse[ Time Frame: Week 0, week 104 ]
  Measured in beats per minute
• Change in amylase[ Time Frame: Week 0, week 104 ]
  Measured in U/L
• Change in lipase[ Time Frame: Week 0, week 104 ]
  Measured in U/L
• Change in calcitonin[ Time Frame: Week 0, week 104 ]
  Measured in ng/L

This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 2 years. The participants will have 19 clinic visits and 15 phone calls with the study doctor.

• Drug: Semaglutide
  Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
• Drug: Placebo (Semaglutide)
  S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks

• Experimental: Semaglutide
  Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
• Placebo Comparator: Placebo
  Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.